UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan

详细信息    查看全文

• 作者：Satoshi Yamasaki (1)
  Kazuki Tanimoto (1) (2)
  Kentarou Kohno (1)
  Masanori Kadowaki (1)
  Ken Takase (1)
  Seiji Kondo (1) (3)
  Akira Kubota (1)
  Morishige Takeshita (4)
  Seiichi Okamura (1)
  
  1. Department of Hematology and Clinical Research Institute ; National Hospital Organization Kyushu Medical Center ; 1-8-1 Jigyohama ; Chuo-Ku ; Fukuoka ; 810-8563 ; Japan
  2. Department of Hematology/Oncology ; Japanese Red Cross Fukuoka Hospital ; Fukuoka ; Japan
  3. Department of Hematology ; Saga Prefectural Hospital Koseikan ; Saga ; Japan
  4. Department of Pathology ; Faculty of Medicine ; Fukuoka University ; Fukuoka ; Japan
  
• 关键词：Elderly patients ; Diffuse large B ; cell lymphoma ; Relapsed ; Irinotecan ; UGT1A1
• 刊名：Annals of Hematology
• 出版年：2015
• 出版时间：January 2015
• 年：2015
• 卷：94
• 期：1
• 页码：65-69
• 全文大小：383 KB
• 参考文献：1. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, BoslyA MP, Nouvel C, Tilly H, Lederlin P, Sebban C, Bri猫re J, Gaulard P, Reyes F (2000) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin鈥檚 lymphoma: final analysis of the prospective LNH87-2 protocol鈥攁 groupe d鈥橢tude des lymphomes de l鈥橝dulte study. J Clin Oncol 18:3025鈥?030
  2. Sarkozy C, Coiffier B (2013) Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties. Clin Cancer Res 19:1660鈥?669 CrossRef
  3. Suzumiya J, Suzushima H, Maeda K, Okamura S, Utsunomiya A, Shibuya T, Tamura K; Kyushu Hematology Organization for Treatment Study Group (2004) Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma. Int J Hematol 79:266鈥?70 CrossRef
  4. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182鈥?194
  5. Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PloS One 8:e58489 CrossRef
  6. Araki K, Fujita K, Ando Y, Nagashima F, Yamamoto W, Endo H, Miya T, Kodama K, Narabayashi M, Sasaki Y (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255鈥?259 CrossRef
  7. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237鈥?244 CrossRef
  8. Kobayashi M, Hazama S, Takahashi K, Oba K, Okayama N, Nishioka M, Hinoda Y, Oka M, Okamoto K, Maeda H, Nakamura D, Sakamoto J, Mishima H (2012) Is there diversity among / UGT1A1 polymorphism in Japan. World J Gastrointest Oncol 4:170鈥?75 CrossRef
  9. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579鈥?86 CrossRef
  10. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50:604鈥?10 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Hematology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0584

文摘

The uridine diphosphate glucuronosyltransferase (UGT) gene 1A1*6 polymorphism, which affects irinotecan metabolism, has been associated with improved survival in lymphoma patients treated with of carboplatin, dexamethasone, etoposide and irinotecan (CDE-11). This study assessed the efficacy of CDE-11 relative to the UGT1A1*6 polymorphism in 27 elderly patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for high-dose chemotherapy plus autologous stem cell transplantation. The 2-year survival rate after initial CDE-11 treatment was significantly higher in patients with than without UGT1A1*6 (57% vs. 5%). The most common grade 4 adverse event in patients with the UGT1A1*6 genotypes was neutropenia (88.9%), but there were no gastrointestinal adverse events or treatment-related deaths. Disease progression was the most frequent cause of death. CDE-11 was well tolerated and provided clinical benefit to elderly patients with relapsed or refractory diffuse large B-cell lymphoma. The response to CDE-11 likely correlated with UGT1A1*6 polymorphisms, but further prospective studies are warranted to optimize irinotecan-based chemotherapies relative to UGT1A1 polymorphism.